Would you use OncoType in a postmenopausal female with HR+/HER2- with LN involvement who clinically meets RxPONDER criteria of 1-3 LN to guide the use of neoadjuvant chemotherapy?

Yes. If I am asked to consider neoadjuvant therapy in a postmenopausal woman with an ER/PR+, HER2 negative cancer, who is otherwise a candidate for chemotherapy, I will start the endocrine therapy and send OncotypeDX to make sure that we are not leaving out an important part of her management, i.e. ...

I am not sure if I would. Having seen unimpressive results on my patients I've enrolled on ALTERNATE trial and the unimpressive preliminary results of the ALTERNATE trial, I believe neoadjuvant approach is not as promising as it is in HER-2 positive or triple negative breast cancer setting.

ALTERNAT...